Last updated: 2026-10-14 03:38:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Bausch + Lomb Corporation (BLCO) operates in the OPHTHALMIC GOODS sector and is listed on NYSE. The stock is currently priced at $15.80, with a market capitalisation of $6.18B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $14.39 to $18.92. This page covers its latest market performance, valuation, price trends and company information.
$6.18B | |
$16.14 | |
$21.95 | |
$10.45 | |
$16.07 | |
716.84K | |
437.02K | |
-- | |
$18.92 | |
$14.39 | |
-- | |
-- |
Bausch + Lomb Corporation (BLCO) last closed at $16.07 as of 2026-10-13 23:31:00, unchanged from the previous close of $16.07.
During the latest regular trading session, BLCO traded between $10.45 and $21.95, with a volume of 716.84K shares. The closing price was near the middle and near the lower end of its 52-week range.
Over the past seven days, Bausch + Lomb Corporation (BLCO) moved from $17.11 to $15.80, representing a decline of 7.66% ($1.31).
The stock traded between $15.47 and $17.50 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 718.99 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 31.2%
BLCO is currently trading at $15.80, placing it 31.2% of the way from its 52-week low of $14.39 to its 52-week high of $18.92. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
| Industry | OPHTHALMIC GOODS |
| Employees | 13000 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of Bausch + Lomb Corporation (BLCO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.